Andrew LaFrence Joins Biothera Board of Directors
EAGAN, MN — August 29, 2011 — Andrew LaFrence, chief financial officer of CNS Therapeutics and a former KPMG audit partner, has joined the Board of Directors of Biothera, the immune health company announced today.
“Andrew is a financial expert and welcomed addition to our board,” said Dan Conners, Biothera chairman. “The depth of his experience in audit, finance, SEC reporting and guidance of late-stage private companies will enable Andrew to make a significant contribution to Biothera.”
During his 26-year career with KPMG, Mr. LaFrence became an audit partner and led the company’s Twin Cities Life Sciences and Emerging Companies practice while serving as a member of KPMG’s national Venture Capital practice.
He frequently consulted with clients on a wide variety of topics, including capital formation and structure, buy versus lease, compensation and human resources, working capital management and business development. Clients have included a wide range of companies ranging from large multinational enterprises to pre-revenue, venture capital-backed enterprises.
Earlier this year Mr. LaFrence became CFO of CNS Therapeutics, a post-revenue, venture capital-backed intrathecal drug company.
About Biothera, the immune health company
Biothera is a biotechnology company dedicated to improving immune health. The company is commercializing its unique technology platform through two business groups. Biothera’s Pharmaceutical Group is conducting multiple clinical trials for the development of a drug that mobilizes the innate immune system to fight most types of cancer. The company’s Healthcare Group is a leading provider of natural immune health ingredients for the functional food and beverage, dietary supplement, cosmetic and animal nutrition markets.
Contact:
David Walsh
VP Communications
Biothera, the Immune Health Company
651-256-4606